Kyle Fraher, M.S., joined RayThera in January 2024 serving as its Senior Vice President, Development. Kyle has more than 20 years of experience in drug development, from preclinical and clinical development through product approval. Her expertise is in R&D operations, project management, and program leadership. Prior to RayThera, Kyle was the Vice President, Program Management at XinThera before its acquisition by Gilead in May 2023. Prior to XinThera, Kyle was Vice President of Program Management at Lengo Therapeutics, until its acquisition by Blueprint Medicines in December 2021. She previously worked in clinical operations, development and program management/leadership at Intercept Pharmaceuticals, Arena Pharmaceuticals, Biogen, and Genentech. Kyle received a B.S. in Anthropology and Human Biology from Emory University and a M.S. in Biostatistics and Epidemiology from Georgetown University.
.webp)